Tesofensine: Clinical & Research Findings on Metabolic Activity and Longevity
Tesofensine is a triple monoamine reuptake inhibitor (serotonin, dopamine, and norepinephrine) originally investigated
for neurodegenerative diseases but later studied for its powerful impact on metabolic activity, energy expenditure, and body weight regulation.
Its role in modulating metabolic and aging-related pathways has made it an intriguing subject for longevity research.
Why Tesofensine is Important for Metabolic Research
Tesofensineโs primary mechanism is blocking reuptake of serotonin, dopamine, and norepinephrine, which enhances satiety and
increases resting energy expenditure. Clinical studies have shown that subjects experienced significant weight reduction
and improvements in metabolic biomarkers. This makes Tesofensine an important compound in the investigation of
obesity, metabolic syndrome, and age-related energy dysregulation.
For laboratory procurement, visit the official page:
Tesofensine 500mcg research peptide
.
Tesofensine and Longevity Pathways
While not an anti-aging drug, Tesofensineโs ability to alter energy balance, body composition, and neurotransmitter activity
links it indirectly to longevity research. Metabolic efficiency and weight control are considered
important contributors to healthy aging, and Tesofensine has shown potential in helping maintain lean mass and reduce fat accumulation.
This has led to growing scientific interest in Tesofensineโs role in healthy lifespan extension models,
especially in combination with diet and exercise interventions.
Mechanism of Action
- Blocks presynaptic reuptake of serotonin, dopamine, and norepinephrine.
- Promotes satiety and reduces appetite in experimental and clinical settings.
- Increases resting metabolic rate and energy expenditure.
- Improves metabolic biomarkers relevant to cardiovascular and aging health.
References (max 2)
- Astrup A, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomized, double-blind, placebo-controlled trial.
Lancet. 2008;372(9653):1906โ1913.
PubMed - Schmidt L, et al. Tesofensine, a novel monoamine reuptake inhibitor, in the treatment of obesity: effects on appetite and energy metabolism.
Obesity (Silver Spring). 2010;18(2):295โ301.
PubMed
Compliance & Research-Only Disclaimer
Pure Tested Peptides provides Tesofensine strictly for laboratory research use only.
All content above is for scientific and educational purposes. Products are not medicines,
not intended for human consumption, and have not been evaluated or approved by the FDA to diagnose,
treat, cure, or prevent any disease.
